Trial · NCT01945021
Results by group176
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 176
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Independent Radiology Reviewed Overall Objective Response (ORR) | Crizotinib 250 mg | 88 | Participants | ||
| IRR-Assessed Duration of Response (DR) | Crizotinib 250 mg | 19.7 | 95% Confidence Interval 14.1 to NA | Months | |
| IRR-Assessed Time to Tumor Response (TTR) | Crizotinib 250 mg | 1.9 | Full Range 1.6 to 15.8 | Months | |
| IRR Assessed Disease Control Rate (DCR) at 8 Weeks | Crizotinib 250 mg | 88.2 | 95% Confidence Interval 81.3 to 93.2 | Percentage of participants | |
| IRR-Assessed Progression Free Survival (PFS) | Crizotinib 250 mg | 15.9 | 95% Confidence Interval 12.9 to 24.0 | Months | |
| Overall Survival (OS) | Crizotinib 250 mg | 44.2 | 95% Confidence Interval 32.0 to NA | Months | |
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs | Crizotinib 250 mg | Incidence of All-Causality Adverse Events | 127 | Participants | |
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs | Crizotinib 250 mg | Incidence of All-Causality Serious Adverse Events | 46 | Participants | |
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs | Crizotinib 250 mg | Incidence of Treatment Related Adverse Events | 124 | Participants | |
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs | Crizotinib 250 mg | Incidence of Treatment Related Serious Adverse Events | 11 | Participants | |
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs | Crizotinib 250 mg | Incidence of All-Causality Grade 3-4 Adverse Event | 68 | Participants | |
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs | Crizotinib 250 mg | Incidence of Treatment Related Grade 3-4 Adverse Event | 41 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Hemoglobin Increased: Baseline Grade 0 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Hemoglobin Increased: Baseline Grade 1 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Hemoglobin Increased: Baseline Grade 2 to Worst Grade 3 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Anemia: Baseline Grade 0 to Worst Grade 3 | 2 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Anemia: Baseline Grade 1 to Worst Grade 3 | 1 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Anemia: Baseline Grade 2 to Worst Grade 3 | 5 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Anemia: Baseline Grade 0 to Worst Grade 4 | 0 | Participants | |
| Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 | Crizotinib 250 mg | Anemia: Baseline Grade 1 to Worst Grade 4 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01945021/results